Theraclion Announces Its Half-year Financial Results for 2023 and Provides an Update on the Execution of Its Strategy - Seite 2

Investment in technology and treatment protocols

In K€

30/06/2023

30/06/2022

Var. %

Turnover

981

347

+183%

Grants

0

7

-92%

Total operating income

981

354

+177%

Purchase of goods

(532)

(143)

+272%

External expenses

(1,115)

(1,746)

-36%

Staff costs

(1,957)

(1,735)

+13%

Other operating expenses

(557)

(173)

+222%

Total operating expenses

(4,161)

(3,797)

+10%

Operating profit

(3,179)

(3,443)

-8%

Financial result

(65)

(40)

+63%

Non-current income

263

350

-25%

Research tax credit

504

492

+2%

Net income

(2,476)

(2,561)

- 3%